Skip to main content
Figure 2 | BMC Veterinary Research

Figure 2

From: Evaluation of the adverse event profile and pharmacodynamics of toceranib phosphate administered to dogs with solid tumors at doses below the maximum tolerated dose

Figure 2

Toceranib Cmax concentrations. Shown are the median Cmax concentrations of dogs treated with toceranib in this study. These are presented for each time point of collection (days 0, 7, 14, and 30) by dose range. For all dose ranges above 2.4 mg/kg, Cmax was above the 40 ng/ml concentration of toceranib predicted to be associated with effective target inhibition.

Back to article page

BMC Veterinary Research

ISSN: 1746-6148

Contact us